AbbVie stock gains as RINVOQ wins European approval
📈 AbbVie stock opened near its 52-week high of $267.47 following European Commission approval for RINVOQ in pediatric patients.
💊 The regulatory decision extends RINVOQ's use to children with active polyarticular juvenile idiopathic arthritis, adding a new growth segment.
📊 Q2 revenue reached $16.99 billion, representing a 10.2% increase from the prior-year period.
💰 The company reported EPS of $3.65 for the quarter ended June 30, 2026, beating consensus estimates by $0.04.
🎯 Revenue exceeded analyst expectations by $0.19 billion during the second quarter of fiscal year 2026.
⚠️ Analysts described the full-year EPS outlook as a slight miss against current market expectations.
Bullish Signals
- AbbVie received European Commission approval for RINVOQ in children with active polyarticular juvenile idiopathic arthritis, expanding its key growth product portfolio.
- Q2 revenue grew 10.2% year-over-year to $16.99 billion, demonstrating strong top-line momentum.
- The company beat EPS consensus estimates by $0.04 with a reported quarterly earnings per share of $3.65.
Risk Factors
- Analysts characterized the full-year EPS outlook as a slight miss against expectations, creating potential downside pressure.
- The stock trades near its 52-week high with limited room for error given the market capitalization of $468.31 billion.
Full Analysis
AbbVie Inc. shares opened at $265.06 on September 22, 2026, near its 52-week high of $267.47, following a significant regulatory win for its key growth product RINVOQ. The European Commission approved the drug for use in children with active polyarticular juvenile idiopathic arthritis, expanding the treatment setting for this biologic agent.
Financially, AbbVie reported strong performance for the quarter ended June 30, 2026, with revenue rising 10.2% year-over-year to $16.99 billion. The company delivered an earnings per share (EPS) of $3.65, beating analyst consensus estimates by $0.04 and topping revenue expectations by $0.19 billion.
Despite the positive quarterly results and new drug approval, coverage noted that the full-year EPS outlook was a slight miss against expectations. With a market capitalization of approximately $468.31 billion, the stock trades at a valuation where earnings disappointments are closely scrutinized by investors.
